Abstract

Abstract: Treatment of fungal infections is very difficult because of the limited therapeutic arsenal and the emergence of resistance to the two major antifungal classes: azoles and echinocandins. Consequently, finding new targets and new therapeutic strategies is a priority. The protein kinase Pkc1 of Candida albicans (CaPkc1), one of the key proteins involved in MAPK pathways, is described as a regulator of cell wall integrity during growth, morphogenesis, and response to cell wall stress. Therefore, the discovery of CaPkc1 inhibitory molecules can open up new and promising prospects in the development of new antifungal drugs that inhibit CaPkc1. In this study, we evaluated the CaPkc1 inhibitory activity of three benzofuro[3,2-d]pyrimidine derivatives at three different concentrations of 50 µM, 100 µM, and 150 µM. A concentration of 100 μM was optimal for CaPkc1 inhibitory activity with all three benzofuro[3,2-d]pyrimidine derivatives.
 Keywords: Benzofuro[3,2-d]pyrimidine, CaPkc1, Candida albicans, antifungal activity. 
 

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.